Highest-materiality recent filing
Atara CAO to depart July 17; Kevin Sarney appointed interim CFO
Yanina Grant-Huerta, Chief Accounting Officer, notified on June 22 that employment ends July 17, 2026.
Q1 2026 net loss $4.1M; cash runway extended; FDA agrees path for tab-cel BLA resubmission
Net loss $4.1M ($0.29 diluted EPS) vs net income $38.0M ($3.50 diluted) in Q1 2025.
Atara biotherapeutics gets FDA alignment on tab-cel BLA resubmission path
Type A meeting with FDA was productive; FDA agreed single-arm study with historical control could support future application.
Atara Biotherapeutics receives Nasdaq delisting notice for market value deficiency
Nasdaq notified Atara on April 30, 2026, that its MVLS fell below $50M for 30 consecutive business days.
Atara reports FY 2025 net income of $32.7M; cash runway extended through YE 2026
Net income of $32.7M ($2.61 per share) in FY 2025 vs. net loss of $85.4M in FY 2024.
Atara and Pierre Fabre request FDA Type A meeting for tabelecleucel BLA resubmission
Pierre Fabre submitted Type A meeting request to FDA to address CRL issues for tabelecleucel (EBVALLO) BLA.
Atara defers $9M milestone payment to HCRx to Jan 2028; issues 400K share warrant
HCRx agreed to extend $9.0M milestone payment due from June 30, 2026 to Jan 1, 2028.
FDA issues CRL for Atara's EBVALLO BLA, reversing prior stance on trial adequacy
FDA CRL received Jan 9, 2026; confirms GMP issues resolved but claims ALLELE trial inadequate for accelerated approval.
Atara Q3 net loss $4.3M; cash $13.7M; tab-cel BLA PDUFA Jan 10, 2026
Cash and equivalents $13.7M as of Sep 30, 2025, down from $22.3M at Jun 30.
Atara Q2 net income $2.4M; tab-cel BLA accepted with Jan 10, 2026 PDUFA date
Cash, equivalents and short-term investments $22.3M at June 30, up from $13.8M at March 31.
Atara resubmits tab-cel BLA to FDA for EBV+ PTLD; cash ~$22M, runway into Q1 2026
Atara resubmitted BLA to FDA for tabelecleucel (tab-cel) for EBV+ PTLD after CRL related to manufacturing observations.
Gross proceeds ~$16M from 834,237 shares at $6.61/share and pre-funded warrants for 1,587,108 shares at $6.6099.
Atara Q1 net income $38M; FDA lifts EBVALLO holds; $16M offering closes May 16
Net income of $38.0M ($3.50 diluted EPS) vs net loss of $31.8M in Q1 2024; revenue $98.1M, up from $27.4M, driven by Pierre Fabre milestone.
Atara Biotherapeutics reduces workforce by ~30% to retain ~23 employees
Approximately 30% workforce reduction, retaining ~23 employees; expected completion by August 2025.
FDA lifts clinical hold on Atara's EBVALLO program; Type A meeting granted
FDA lifted clinical hold on EBVALLO (tabelecleucel) IND applications, allowing resumption of Phase 3 ALLELE and Phase 2 label-expansion studies.
Transferred all manufacturing responsibility for tab-cel to Pierre Fabre as of March 31, 2025; Pierre Fabre will manufacture and supply worldwide at its cost.
Atara CFO/COO Eric Hyllengren to depart March 31; Yanina Grant-Huerta named CAO
CFO/COO Eric Hyllengren's employment ends March 31, 2025; he will provide consulting through July 31 at an hourly rate.
Net loss of $12.7M ($1.19/share) for Q4 2024 vs $60.5M loss in Q4 2023; full year loss $85.4M.
Atara Biotherapeutics cuts 50% of workforce, discontinues two CAR T programs
Reducing workforce by ~50%; expected to substantially complete by June 2025.
Atara Biotherapeutics cuts workforce by ~50%; expects $7.5M severance costs
Workforce reduction impacts ~50% of current employees; completion expected by June 2025.
Atara Biotherapeutics receives FDA clinical hold on EBVALLO and ATA3219 programs
FDA clinical hold on EBVALLO and ATA3219 studies due to GMP compliance issues at third-party manufacturer.
Atara receives FDA Complete Response Letter for EBVALLO BLA due to third-party manufacturing issues
FDA CRL solely related to third-party manufacturer inspection findings; no clinical efficacy/safety issues, no new trials requested.
Atara Q3 net loss narrows to $21.9M; tab-cel PDUFA Jan 15, 2025; CLO departs
Net loss $21.9M ($2.93/share) vs $69.8M ($16.40) YoY; revenue rose to $40.2M from $2.1M.
Atara raises ~$36M via registered direct offering; appoints Gregory Ciongoli to board
Registered direct offering of 758,900 shares and pre-funded warrants for up to 3,604,780 shares at $8.25/$8.2499.
Atara CEO Pascal Touchon to step down, succeeded by Cokey Nguyen; Q2 net loss narrows to $19M
Pascal Touchon steps down as CEO effective Sep 9, 2024, becomes Chairman; Cokey Nguyen promoted to President and CEO.
Atara Biotherapeutics' tab-cel BLA accepted for priority review by FDA; PDUFA Jan 15, 2025
BLA for tabelecleucel (tab-cel) accepted for priority review to treat EBV+ PTLD in patients ≥2 years with ≥1 prior therapy.
Reverse stock split at 1-for-25 ratio effective June 20, 2024 at 12:01 a.m. ET; post-split trading starts same day.
Atara shareholders approve reverse stock split (1:4–1:30) and 2024 Equity Incentive Plan
Reverse stock split approved at board's discretion (ratio 1-for-4 to 1-for-30), board may abandon.
Atara Q1 net loss narrows to $31.8M; tab-cel BLA on track for Q2 2024 submission
Q1 2024 net loss of $31.8M ($0.23/sh) vs $74.8M ($0.72/sh) in Q1 2023; revenue rose to $27.4M from $1.2M on Pierre Fabre partnership.
Atara posts Q4 loss $0.56/sh; tab-cel BLA submission on track for Q2 2024
Q4 net loss $60.5M ($0.56/diluted share); FY 2023 net loss $276.1M ($2.61/diluted share).
Atara raises $15M via pre-funded warrants; Nasdaq warns of bid price deficiency
Gross proceeds of ~$15M from sale of pre-funded warrants to purchase up to 27,272,727 shares at $0.55/warrant.
Atara cuts 25% of workforce, restructures to focus on CAR-T; CMO departs
Workforce reduction of ~25% (approx. 56 employees) expected to complete by May 2024; severance costs ~$4.5M.
Pierre Fabre gets development, manufacturing, commercialization rights for tab-cel in US and all remaining markets.
EMBOLD misses primary endpoint; treatment arm CDI 6% vs 33% in Phase 1; placebo rate 16% exceeded expected 4-6%.
Atara expands tab-cel partnership worth up to $640M, cuts workforce 30%, Q3 loss $69.8M
Expanded global tab-cel deal with Pierre Fabre: up to $640M in payments, ~$30M upfront and $100M regulatory milestones, plus tiered double-digit royalties.
Atara Biotherapeutics establishes $100M ATM equity facility with TD Cowen
Entered into an at-the-market (ATM) sales agreement with TD Cowen for up to $100M in common stock.
Atara announces FDA agreement on tab-cel comparability; BLA submission planned Q2 2024
FDA and Atara aligned on analytical comparability between manufacturing process versions of tab-cel.
Atara Q2 net loss $71.1M; IND cleared for ATA3219; tab-cel BLA meeting scheduled
Net loss of $71.1M ($0.68 per share) vs net income of $18.5M ($0.18) in Q2 2022, which included one-time gains.
On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026.
On June 22, 2026, Atara Biotherapeutics, Inc. (the “Company”) notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026.
On June 11, 2026, the Board of Directors (the “ Board ”) of Atara Biotherapeutics, Inc. (the “ Company ”) appointed Brian Cherry to serve as a member of the Board as a Class I director, effective June 11, 2026 (the “ Effective Date ”).
the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board
the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board
On March 25, 2025, it was agreed that the employment of Eric Hyllengren, the Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (the “ Company ”), would end effective March 31, 2025.
On March 31, 2025, the Company appointed Yanina Grant-Huerta as the Company’s Chief Accounting Officer and principal accounting officer, effective March 31, 2025.
On November 8, 2024, it was agreed that the employment of Amar Murugan, the Company’s Chief Legal Officer, would end effective November 8, 2024.
On October 14, 2024, the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc. (the “Company”) appointed Eric Hyllengren to serve as the Company’s Chief Operating Officer, in addition to his role as the Company’s Chief Financial Officer.
On September 3, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed, effective as of and contingent upon the Closing Date (as defined below), Mr. Gregory A. Ciongoli to serve as a member of the Board.
On August 10, 2024, Pascal Touchon notified the Board of Directors (the “Board”) of the Company of his decision to step down as the Company’s President and Chief Executive Officer, effective as of September 9, 2024
Effective as of the Separation Date, Dr. Touchon will be appointed as Chairman of the Board and will remain a member of the Board.
Max materiality 0.85 · Median 0.70 · Most common event other_material